These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. De Novo Minimal Change Disease following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor. Marinaki S; Kolovou K; Liapis G; Skalioti C; Tsiakas S; Boletis I Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056345 [TBL] [Abstract][Full Text] [Related]
48. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735 [TBL] [Abstract][Full Text] [Related]
49. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ; MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654 [TBL] [Abstract][Full Text] [Related]
50. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges. Sagili Anthony DP; Sivakumar K; Venugopal P; Sriram DK; George M Clin Drug Investig; 2021 Jun; 41(6):499-509. PubMed ID: 33754328 [TBL] [Abstract][Full Text] [Related]
51. The discovery and development of mRNA vaccines for the prevention of SARS-CoV-2 infection. Xue VW; Wong SCC; Li B; Cho WCS Expert Opin Drug Discov; 2023 Jul; 18(7):769-780. PubMed ID: 37237360 [TBL] [Abstract][Full Text] [Related]
52. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397 [TBL] [Abstract][Full Text] [Related]
53. Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies. Ozakbas S; Baba C; Dogan Y; Cevik S; Ozcelik S; Kaya E Mult Scler Relat Disord; 2022 Feb; 58():103486. PubMed ID: 35032878 [TBL] [Abstract][Full Text] [Related]
54. Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports. Mohamed L; Madsen AMR; Schaltz-Buchholzer F; Ostenfeld A; Netea MG; Benn CS; Kofoed PE BMC Infect Dis; 2021 Dec; 21(1):1264. PubMed ID: 34930152 [TBL] [Abstract][Full Text] [Related]
56. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Jain S; Venkataraman A; Wechsler ME; Peppas NA Adv Drug Deliv Rev; 2021 Dec; 179():114000. PubMed ID: 34637846 [TBL] [Abstract][Full Text] [Related]
57. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.]. Casas Fischer R Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347 [TBL] [Abstract][Full Text] [Related]
58. Clinical Development of mRNA Vaccines: Challenges and Opportunities. August A; Brito L; Paris R; Zaks T Curr Top Microbiol Immunol; 2022; 440():167-186. PubMed ID: 35906319 [TBL] [Abstract][Full Text] [Related]
59. Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster. Silva ARD; Villas-Boas LS; Paula AV; Tozetto-Mendoza TR; Honorato L; Witkin SS; Mendes-Correa MC Rev Inst Med Trop Sao Paulo; 2022; 64():e43. PubMed ID: 35730869 [No Abstract] [Full Text] [Related]
60. Current Developments and Challenges of mRNA Vaccines. Chen J; Chen J; Xu Q Annu Rev Biomed Eng; 2022 Jun; 24():85-109. PubMed ID: 35231177 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]